← Leaderboards
Birgit Knoechel
Dana-Farber Cancer Inst
$3,667,430
Attributed
$3,667,430
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $2.6M · FY2015–25$5M$3.8M$2.5M$1.3M$0
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$8,796,776 · 5
By mechanism
P01$5,964,316 · 3
R01$1,946,860 · 1
K08$885,600 · 1
Top collaborators
No co-investigators on record.
Most similar at Dana-Farber Cancer Inst
Same institution · by research overlap
- Gregory Howard Bird$3,139,726
- James Laurence Labelle$842,293
- Rosalind A Segal$29,230,271
- David Marc Weinstock$10,844,261
- Wayne A. Marasco$43,896,916
Others in their field
Top investigators on “Relapse”
- Ralph Parchment · Leidos Biomedical Research, Inc.$141,315,269
- Charles A Coltman · Southwest Oncology Group$124,514,512
- Mary M Horowitz · Medical College Of Wisconsin$85,160,686
- Monica M Bertagnolli · Strang Cancer Prevention Center$41,995,734
- Effie W Petersdorf · Fred Hutchinson Cancer Research Center$29,676,600
- Misty Ward Stevens · Intervexion Therapeutics, Llc$28,867,910
Research focus
RelapseIn VitroCellsT-LymphocyteSuccessRefractoryMolecularResistance MechanismNovel StrategiesEpigenetic ProcessPathway InteractionsResponseSamplingChromatinProteinsMutationClinical TrialsNovel Therapeutic InterventionRefractory DiseaseGeneticMouse ModelChemotherapyOncogenicChild
Grant awards (16)
Mechanisms of immune evasion in T-cell acute lymphoblastic leukemia and its therapeutic implications$352,270
R01 · FY2025 · CA · contact PI
Mechanisms of immune evasion in T-cell acute lymphoblastic leukemia and its therapeutic implications$238,971
R01 · FY2024 · CA · contact PI
Mechanisms of immune evasion in T-cell acute lymphoblastic leukemia and its therapeutic implications$146,490
R01 · FY2024 · CA · contact PI
Informed Combination Strategies for Peripheral T-cell Lymphomas$1,698,229
P01 · FY2023 · CA · contact PI
Mechanisms of immune evasion in T-cell acute lymphoblastic leukemia and its therapeutic implications$397,633
R01 · FY2023 · CA · contact PI
Synergistic combinations that target apoptosis induction in PTCL$382,168
P01 · FY2023 · CA · contact PI
Informed Combination Strategies for Peripheral T-cell Lymphomas$1,698,229
P01 · FY2022 · CA · contact PI
Synergistic combinations that target apoptosis induction in PTCL$452,802
P01 · FY2022 · CA · contact PI
Mechanisms of immune evasion in T-cell acute lymphoblastic leukemia and its therapeutic implications$405,748
R01 · FY2022 · CA · contact PI
Informed Combination Strategies for Peripheral T-cell Lymphomas$1,732,888
P01 · FY2021 · CA · contact PI
Mechanisms of immune evasion in T-cell acute lymphoblastic leukemia and its therapeutic implications$405,748
R01 · FY2021 · CA · contact PI
Epigenetic mechanisms of drug resistance in T-cell acute lymphoblastic leukemia$177,120
K08 · FY2019 · CA · contact PI
Epigenetic mechanisms of drug resistance in T-cell acute lymphoblastic leukemia$177,120
K08 · FY2018 · CA · contact PI
Epigenetic mechanisms of drug resistance in T-cell acute lymphoblastic leukemia$177,120
K08 · FY2017 · CA · contact PI
Epigenetic mechanisms of drug resistance in T-cell acute lymphoblastic leukemia$177,120
K08 · FY2016 · CA · contact PI
Epigenetic mechanisms of drug resistance in T-cell acute lymphoblastic leukemia$177,120
K08 · FY2015 · CA · contact PI